How to choose the right real-time RT-PCR primer sets for the SARS-CoV-2 genome detection?
Copyright © 2021 Elsevier B.V. All rights reserved..
OBJECTIVES: The SARS-CoV-2 pandemic has created an unprecedented need for rapid large-scale diagnostic testing to prompt clinical and public health interventions. Currently, several quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assays recommended by the World Health Organization are being used by clinical and public health laboratories and typically target regions of the RNA-dependent RNA polymerase (RdRp), envelope (E) and nucleocapsid (N) coding region. However, it is currently unclear if results from different tests are comparable. This study aimed to clarify the clinical performances of the primer/probe sets designed by US CDC and Charité/Berlin to help clinical laboratories in assay selection for SARS-CoV-2 routine detection.
METHODS: We compared the clinical performances of the recommended primer/probe sets using one hundred nasopharyngeal swab specimens from patients who were clinically diagnosed with COVID-19. An additional 30 "pre-intervention screening" samples from patients who were not suspected of COVID-19 were also included in this study. We also performed sequence alignment between 31064 European SARS-CoV-2 and variants of concern genomes and the recommended primer/probe sets.
RESULTS: The present study demonstrates substantial differences in SARS-CoV-2 RNA detection sensitivity among the primer/probe sets recommended by the World Health Organization especially for low-level viral loads. The alignment of thousands of SARS-CoV-2 sequences reveals that the genetic diversity remains relatively low at the primer/probe binding sites. However, multiple nucleotide mismatches might contribute to false negatives.
CONCLUSION: An understanding of the limitations depending on the targeted genes and primer/probe sets may influence the selection of molecular detection assays by clinical laboratories.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:295 |
|---|---|
| Enthalten in: |
Journal of virological methods - 295(2021) vom: 06. Sept., Seite 114197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anantharajah, Ahalieyah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 23.07.2021 Date Revised 17.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jviromet.2021.114197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325828873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325828873 | ||
| 003 | DE-627 | ||
| 005 | 20231225193255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jviromet.2021.114197 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325828873 | ||
| 035 | |a (NLM)34033854 | ||
| 035 | |a (PII)S0166-0934(21)00136-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Anantharajah, Ahalieyah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How to choose the right real-time RT-PCR primer sets for the SARS-CoV-2 genome detection? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2021 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: The SARS-CoV-2 pandemic has created an unprecedented need for rapid large-scale diagnostic testing to prompt clinical and public health interventions. Currently, several quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assays recommended by the World Health Organization are being used by clinical and public health laboratories and typically target regions of the RNA-dependent RNA polymerase (RdRp), envelope (E) and nucleocapsid (N) coding region. However, it is currently unclear if results from different tests are comparable. This study aimed to clarify the clinical performances of the primer/probe sets designed by US CDC and Charité/Berlin to help clinical laboratories in assay selection for SARS-CoV-2 routine detection | ||
| 520 | |a METHODS: We compared the clinical performances of the recommended primer/probe sets using one hundred nasopharyngeal swab specimens from patients who were clinically diagnosed with COVID-19. An additional 30 "pre-intervention screening" samples from patients who were not suspected of COVID-19 were also included in this study. We also performed sequence alignment between 31064 European SARS-CoV-2 and variants of concern genomes and the recommended primer/probe sets | ||
| 520 | |a RESULTS: The present study demonstrates substantial differences in SARS-CoV-2 RNA detection sensitivity among the primer/probe sets recommended by the World Health Organization especially for low-level viral loads. The alignment of thousands of SARS-CoV-2 sequences reveals that the genetic diversity remains relatively low at the primer/probe binding sites. However, multiple nucleotide mismatches might contribute to false negatives | ||
| 520 | |a CONCLUSION: An understanding of the limitations depending on the targeted genes and primer/probe sets may influence the selection of molecular detection assays by clinical laboratories | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical performance | |
| 650 | 4 | |a In silico analysis | |
| 650 | 4 | |a Molecular detection | |
| 650 | 4 | |a Real-time RT PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a DNA Primers |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 700 | 1 | |a Helaers, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Defour, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Olive, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Kabera, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Croonen, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Deldime, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Vaerman, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Barbée, Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Bodéus, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Scohy, Anais |e verfasserin |4 aut | |
| 700 | 1 | |a Verroken, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Villalobos, Hector |e verfasserin |4 aut | |
| 700 | 1 | |a Kabamba-Mukadi, Benoît |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of virological methods |d 1981 |g 295(2021) vom: 06. Sept., Seite 114197 |w (DE-627)NLM012608386 |x 1879-0984 |7 nnns |
| 773 | 1 | 8 | |g volume:295 |g year:2021 |g day:06 |g month:09 |g pages:114197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jviromet.2021.114197 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 295 |j 2021 |b 06 |c 09 |h 114197 | ||